Caisse de Depot Et Placement Du Quebec 13F: Adds $75M to GILD Stake
The fund boosted its holdings in Gilead Sciences by 62.6%, adding 594,774 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Caisse de Depot Et Placement Du Quebec added 594,774 shares to its stake in Gilead Sciences, Inc. ($GILD), a 62.64% increase, according to a 13F filing with the SEC dated May 14, 2026. It reported 1,544,223 shares worth $195.10 million at the end of the quarter.
Since the filing, $GILD is down 1.2% after 1 week, down 5.3% after 1 month and up 19.7% to date (from the $130.46 close on May 14, 2026).
Find the original: Caisse de Depot Et Placement Du Quebec 13F filings on SEC EDGAR
GILD
Gilead Sciences, Inc.
Key Points
- Caisse de Depot Et Placement Du Quebec increased its stake in Gilead Sciences, Inc. by 62.6%, adding 594,774 shares to total 1,544,223 shares valued at $191.2 million.
- Gilead Sciences, Inc. has a market cap of about $153.8 billion and a forward P/E ratio of 12.8, trading near $123.84.
- Analysts like Cantor Fitzgerald and Maxim Group have reiterated or upgraded their ratings, with targets as high as $180.
Get $GILD trade alerts by text
We text you when insiders, Congress or big funds trade $GILD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Gilead Sciences, Inc. alert may contain errors. Disclosures
Caisse de Depot Et Placement Du Quebec significantly increased its holdings in Gilead Sciences, Inc. (NasdaqGS: GILD) by 62.6% as of its latest SEC filing. The fund added 594,774 shares, bringing its total to 1,544,223 shares, valued at approximately $191.2 million.
Caisse de Depot Et Placement Du Quebec vs. the S&P 500
Hypothetical returns from Caisse de Depot Et Placement Du Quebec's disclosed trades, not real profit or advice. How we model this.
What Changed in Caisse de Depot Et Placement Du Quebec's Gilead Sciences Position
Caisse de Depot Et Placement Du Quebec boosted its position in Gilead Sciences by 62.6%, increasing its shares from 949,449 to 1,544,223. This substantial addition reflects the fund's growing confidence in Gilead, with the total value of the position now standing at about $191.2 million.
Other Institutional Activity in Gilead Sciences
Among other institutional investors, BlackRock, Inc. reduced its holdings by 4.18 million shares, ending with 119 million shares valued at $16.59 billion, a 3.4% decrease. Vanguard Capital Management LLC opened a new position with 80.65 million shares worth $11.24 billion. FMR LLC increased its stake by 6.33 million shares, bringing its total to 71.91 million shares valued at $10.02 billion, marking a 9.6% increase. State Street Corp slightly trimmed its holdings by 381,933 shares, maintaining 59.86 million shares valued at $8.34 billion, a 0.6% decrease.
Gilead Sciences, Inc. Stock Down 19.7%
Shares of Gilead Sciences, Inc. traded near $123.84 on Friday. The company has a market cap of approximately $153.8 billion. It boasts a P/E ratio of 16.8 and a forward P/E of 12.8, with a relatively low beta of 0.331, indicating less volatility than the market. The stock's 52-week range spans from $106.84 to $157.29, with a 50-day moving average of $130.55 and a 200-day moving average of $129.61. Gilead maintains a current ratio of 1.97 and a quick ratio of 1.54, with a debt-to-equity ratio of 94.64.
Recent Earnings
In its most recent earnings report, Gilead Sciences posted revenue of $29.74 billion, reflecting a 4.4% growth. The company achieved a net margin of 30.99% and a return on equity of 43.36%. Earnings per share stood at $7.36. The next earnings release is scheduled for August 6, 2026.
Dividend
Gilead Sciences offers an annual dividend rate of $3.28, yielding 2.65%. The company's dividend payout ratio is 43.4%.
Insider Buying and Selling at Gilead Sciences, Inc.
Recent insider activity at Gilead Sciences includes planned sales by CFO Andrew Dickinson and Chief Comm & Corp Aff Officer Johanna Mercier, each selling 3,000 shares on June 15, 2026. On June 10, 2026, Dickinson also bought 2,796 shares, while CEO Daniel Patrick O'Day sold 8,779 shares.
Analysts Set New Price Targets
On June 16, 2026, Cantor Fitzgerald reiterated its buy rating on Gilead Sciences with a $155 price target. Maxim Group upgraded the stock to a buy with a $165 target on May 20, 2026. The consensus among 28 analysts is a buy, with an average target price of $157.57.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company based in Foster City, California. It focuses on discovering and developing medicines for unmet medical needs, particularly in HIV, hepatitis, and oncology. The company employs around 17,000 people and is led by CEO Daniel Patrick O'Day.
Bottom Line
This substantial increase by Caisse de Depot Et Placement Du Quebec in Gilead Sciences, Inc. highlights the fund's confidence in the healthcare giant. Investors often track such moves for insights into institutional sentiment. Remember, 13F filings are backward-looking and may not reflect current positions.
Related Filing Alerts
Source: Caisse de Depot Et Placement Du Quebec's 13F filing on $GILD (May 14, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Caisse de Depot Et Placement Du Quebec 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts